Default company panoramic image
Logo

OyaGen

Developing AIDS therapies that enable natural defenses in a path toward a functional cure

  • Stage Product In Development
  • Industry Biotechnology
  • Location Rochester, NY, USA
  • Currency USD
  • Founded September 2003
  • Employees 6
  • Website oyageninc.com

Company Summary

OyaGen seeks to bring to market the anti-HIV drugs targeting Vif and APOBEC3G that solve the problems of viral resistance, a major shortcoming of all current therapies. In the long run, the Company will draw on its core expertise in Editing Enzyme technologies to develop therapies for other disease states.

Team

  • Default avatar
    Harold Charles Smith
    CEO

    Harold Smith is a tenured professor of biochemistry and biophysics at the University of Rochester, School of Medicine and Dentistry. Dr. Smith’s primary function at the University is basic research and in this context he is fully engaged in biomedical laboratory research as well as training postdocs, graduate and undergraduate students. The Smith lab’s primary interest is understanding the composition, regulation and structure of macromolecular c

  • Default avatar
    Thomas Fitchgerald
    COO

    Tom Fitzgerald was named President & CEO of OyaGen in May, 2004, after joining OyaGen as a management consultant in December, 2003. He has provided guidance on commercial issues, regulatory and business development matters. Mr. Fitzgerald has more than 25 years of experience in the biopharmaceutical industry. As an industry consultant, he has provided strategic advice for a range of early stage companies as well as more established domestic and i

Advisors

  • Default avatar
    Nixon Peabody
    Lawyer
    Unconfirmed
    Default avatar
    Janice Tornatore
    Accountant
    Unconfirmed

Previous Investors

  • Default avatar
    Trillium Group LLC|Other Local Angels|
    Unconfirmed
    Default avatar
    NIH NIAID
    Unconfirmed